Effect of the Intralesional Forms of Methylprednisolone Acetate and Methotrexate on Psoriatic Nails
Skinmed. 2024 Mar 18;22(1):35-39. eCollection 2024.ABSTRACTIndividuals with psoriatic nails often have a lower quality of life relative to their counterparts with healthy nails. Methotrexate (MTX), an anti-neoplastic agent, is a longstanding treatment option for nail psoriasis. In the current study, we compared the effects of MTX to that of a corticosteroid, namely, methylprednisolone acetate (i.e., Depo-Medrol®) across individuals with nail psoriasis. We used a cohort study design, and both agents were administered intralesionally. Outcome variables were based on the Nail Psoriasis Severity Index (NAPSI). We quantified t...
Source: Skinmed - March 18, 2024 Category: Dermatology Authors: Riad Kassem Aditya K Gupta Mary A Bamimore Mesbah Talukder Avner Shemer Lee Magal Anna Lyakhovitsky Ralph Daniel Baruch Kaplan Eran Galili Source Type: research
Effect of the Intralesional Forms of Methylprednisolone Acetate and Methotrexate on Psoriatic Nails
Skinmed. 2024 Mar 18;22(1):35-39. eCollection 2024.ABSTRACTIndividuals with psoriatic nails often have a lower quality of life relative to their counterparts with healthy nails. Methotrexate (MTX), an anti-neoplastic agent, is a longstanding treatment option for nail psoriasis. In the current study, we compared the effects of MTX to that of a corticosteroid, namely, methylprednisolone acetate (i.e., Depo-Medrol®) across individuals with nail psoriasis. We used a cohort study design, and both agents were administered intralesionally. Outcome variables were based on the Nail Psoriasis Severity Index (NAPSI). We quantified t...
Source: Skinmed - March 18, 2024 Category: Dermatology Authors: Riad Kassem Aditya K Gupta Mary A Bamimore Mesbah Talukder Avner Shemer Lee Magal Anna Lyakhovitsky Ralph Daniel Baruch Kaplan Eran Galili Source Type: research
Effect of the Intralesional Forms of Methylprednisolone Acetate and Methotrexate on Psoriatic Nails
Skinmed. 2024 Mar 18;22(1):35-39. eCollection 2024.ABSTRACTIndividuals with psoriatic nails often have a lower quality of life relative to their counterparts with healthy nails. Methotrexate (MTX), an anti-neoplastic agent, is a longstanding treatment option for nail psoriasis. In the current study, we compared the effects of MTX to that of a corticosteroid, namely, methylprednisolone acetate (i.e., Depo-Medrol®) across individuals with nail psoriasis. We used a cohort study design, and both agents were administered intralesionally. Outcome variables were based on the Nail Psoriasis Severity Index (NAPSI). We quantified t...
Source: Skinmed - March 18, 2024 Category: Dermatology Authors: Riad Kassem Aditya K Gupta Mary A Bamimore Mesbah Talukder Avner Shemer Lee Magal Anna Lyakhovitsky Ralph Daniel Baruch Kaplan Eran Galili Source Type: research
Population pharmacokinetic analyses of methotrexate in pediatric patients: a systematic review
ConclusionA more rigorous external evaluation needs to be performed before routine clinical use to select the appropriate PopPK model. Further research is necessary to incorporate larger cohorts or pool analyses in specific susceptible pediatric populations to improve the understanding of predicted exposure profiles and covariate identification. (Source: European Journal of Clinical Pharmacology)
Source: European Journal of Clinical Pharmacology - March 18, 2024 Category: Drugs & Pharmacology Source Type: research
The impact of glucocorticoid use on the outcomes of rheumatoid arthritis in a multicenter ultrasound cohort study
ConclusionRA patients treated with glucocorticoids had a higher disease activity at baseline and a poorer response to treatments with b/tsDMARDs than those without glucocorticoids. The states of patients requiring glucocorticoids might be associated with the poor response to the b/tsDMARDs. (Source: International Journal of Rheumatic Diseases)
Source: International Journal of Rheumatic Diseases - March 15, 2024 Category: Rheumatology Authors: Fumiaki Nonaka,
Shoichi Fukui,
Tohru Michitsuji,
Yushiro Endo,
Ayako Nishino,
Toshimasa Shimizu,
Masataka Umeda,
Remi Sumiyoshi,
Tomohiro Koga,
Naoki Iwamoto,
Tomoki Origuchi,
Yukitaka Ueki,
Nobutaka Eiraku,
Takahisa Suzuki,
Akitomo Okada,
Tags: ORIGINAL ARTICLE Source Type: research
Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research
Potential efficacy of T and B lymphocyte-targeted therapies on articular involvement of patients with rheumatoid arthritis and systemic sclerosis overlap syndrome. Results from a 2-centre series of 22 cases
CONCLUSIONS: In patients with RA/SSc overlap syndrome refractory to conventional synthetic-DMARDs, T and B lymphocyte-targeted therapies seem to be a promising therapeutic option to control joint activity.PMID:38489323 | DOI:10.55563/clinexprheumatol/0znf7e (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - March 15, 2024 Category: Rheumatology Authors: Nans Lebel Isabelle Marie Julien Grosjean Pauline Brevet Mathilde Leclercq Ana ël Dumont Herv é Levesque Ygal Benhamou Christian Marcelli Thierry Lequerre Olivier Vittecoq Source Type: research
FIERCE-HN: A Multicenter, Randomized, Placebo-controlled, Phase 3 Study of ficlatuzumab + cetuximab in pts w/ recurrent or Metastatic (R/M) HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)
For patients with R/M HNSCC, current treatments are palliative with anti-PD-1 checkpoint inhibitor +/- platinum and 5-fluorouracil chemotherapy for first-line followed by taxanes, methotrexate, and cetuximab as later-line options. The median overall survival (OS) for R/M patients is 10-13 months, and those with HPV-negative HNSCC face the worst outcomes.[1] Ficlatuzumab is a humanized IgG1 mAB against HGF, the ligand for the c-MET tyrosine kinase receptor. HGF/c-MET pathway dysregulation is frequently observed in HPV-negative HNSCC. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - March 14, 2024 Category: Radiology Authors: J. Bauman, K. Allman, R.I. Haddad Tags: 148 Source Type: research
Toripalimab plus lenalidomide for central nervous system recurrence in refractory CD5(+) diffuse large B-cell lymphoma with MYD88 and CD79B comutation: a case report
CONCLUSIONS: These findings suggest that toripalimab may be a new therapeutic option for central nervous system recurrence in refractory CD5+ DLBCL with MYD88 and CD79B comutation. Further clinical trials are warranted to confirm these results.PMID:38482415 | PMC:PMC10928622 | DOI:10.21037/tcr-23-1638 (Source: Cell Research)
Source: Cell Research - March 14, 2024 Category: Cytology Authors: Xi Chen Zhihan Zhang Junbao Zhang Qiuxiao Yu Junjing Qiu Yajie Xiao Binbin Chen Ping Xu Source Type: research
